


IFW

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

January 28, 2005

Miyabi Grace  
Miyabi Grace



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<b>Application No.</b>	10/763,450	<b>Group Art Unit:</b>	1646
<b>Applicant(s):</b>	Mary Mah Lee Ng; Justin Jang Hann Chu	<b>Examiner:</b>	To be assigned
<b>Filing Date:</b>	January 22, 2004	<b>Docket No.</b>	59419-010101
<b>Title:</b>	MOLECULES, COMPOSITIONS, METHODS AND KITS FOR APPLICATIONS ASSOCIATED WITH FLAVIVIRUS		
	<b>Customer No.</b>	33717	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT [37 C.F.R. § 1.56]**

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

This Information Disclosure Statement is being submitted within three months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. § 1.53(d), or within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application; or before the mailing date of a first Office action on the merits, and therefore, Applicant believes no fee is required;

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.


No fee is believed due with the submission of this paper. However, if the Applicants are mistaken, the Director is authorized to charge any required fee(s) or any underpayment of fee(s), or to credit any overpayments to Deposit Account Number 50-2638, Deposit Account Name Greenberg Traurig, LLP. Please ensure that the Attorney Docket Number is referred to when charging any payments or credits for this case.

Respectfully submitted,

GREENBERG TRAURIG, LLP

Date January 28, 2005

By



Claude Nassif, Ph.D.

Reg. No. 52,061

Tel.: (310) 586-7828

Greenberg Traurig, LLP  
2450 Colorado Avenue, Suite 400  
Santa Monica, California 90404  
Telephone: 310-586-7700  
Facsimile: 310-586-7800

*Complete if Known*

(use as many sheets as necessary)

1	of	4
---	----	---

Application Number	10/763,450
Filing Date	January 22, 2004
First Named Inventor	Mary NG Mah Lee
Art Unit	1646
Examiner Name	To be assigned
Attorney Docket Number	59419-010101

[illegible][illegible]

LA-FS1\314599v01\59419.010101

Examiner  
Signature

Date	
Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Application Number	10/763,450
				Filing Date	January 22, 2004
				First Named Inventor	Mary NG Mah Lee
				Art Unit	1646
				Examiner Name	To be assigned
Sheet	2	of	4	Attorney Docket Number	59419-010101

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Adlish <i>et al.</i> ; Identification of a putative cell receptor for human cytomegalovirus; Virology; 1990; Vol. 176; pp. 337-345.	
		Agnello <i>et al.</i> ; Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor, Proc Natl Acad Sci; Oct 26, 1996; Vol. 96, No. 22; pp. 12766-12771.	
		Atkinson <i>et al.</i> ; Purification and properties of HeLa cell plasma membranes; J Biol Chem; August 25, 1971; Vol. 246, No. 16; pp. 5162-5175.	
		Beasley <i>et al.</i> ; Identification of neutralizing epitopes within structural domain III of the West Nile virus envelop protein; J. Virol.; Dec 2002; Vol. 76, No. 24, pp. 13097-13100.	
		Bielefeldt-Ohmann <i>et al.</i> ; Dengue virus binding to human leukocyte cell lines: receptor usage differs between cell types and virus strains; Virus Res.; 2001; Vol. 73; pp. 81-89.	
		Blau <i>et al.</i> ; Entry and release of measles virus are polarized in epithelial cells; Virology; 1995; Vol. 210; pp. 91-99.	
		Borrow <i>et al.</i> ; Characterization of lymphocytic choriomeningitis virus-binding protein(s): a candidate cellular receptor for the virus; J Virol.; Dec 1992; Vol. 66, No. 12; pp. 7270-7281.	
		Bruett <i>et al.</i> ; Characterization of a membrane-associated protein implicated in visna virus binding and infection; Virology; 2000; Vol. 271; pp. 132-141.	
		Cao <i>et al.</i> ; Identification of $\alpha$ -Dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus; Science; Dec 11, 1998; Vol. 282; pp. 2079-2081.	
		Castle <i>et al.</i> ; Primary structure of the West Nile flavivirus genome region coding for all nonstructural proteins. Virology; 1986; Vol. 149; pp. 10-26.	
		Castle <i>et al.</i> ; Sequence analysis of the viral core protein and the membrane-associated proteins VI and NV2 of the flavivirus West Nile virus and of the genome sequence for these proteins; Virology; 1985; Vol. 145; pp. 227-236.	
		Chen <i>et al.</i> ; Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate; Nat Med; Aug. 1997; Vol. 139, No. 8; pp. 239-251.	

LA-FS1\314599v01\59419.010101

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Application Number	10/763,450
				Filing Date	January 22, 2004
				First Named Inventor	Mary NG Mah Lee
				Art Unit	1646
				Examiner Name	To be assigned
Sheet	3	of	4	Attorney Docket Number	59419-010101

## NON PATENT LITERATURE DOCUMENTS

	Choi <i>et al.</i> ; Reovirus binds to multiple plasma membrane proteins of mouse L fibroblasts; Virology; 1990; Vol. 178; pp. 316-320.	
	Chu <i>et al.</i> ; Infection of polarized epithelial cells with flavivirus West Nile: Polarized entry and egress of virus occur through apical surface; J Gen Virol.; 2002; Vol. 83; pp. 2427-2435.	
	Chu <i>et al.</i> ; Trafficking mechanism of West Nile (Sarafend) virus structural proteins; J Med Virol.; 2002; Vol. 67; pp. 127-136.	
	Cote <i>et al.</i> ; Generation of human monoclonal antibodies reactive with cellular antigens; Proc. Natl. Acad. Sci. USA; April 1983; Vol. 80; pp. 2026-2030.	
	Crane <i>et al.</i> ; Identification of cell membrane proteins that bind visna virus; J Virol.; Nov 1991; Vol. 65, No. 11; pp. 6137-6143.	
	Crill <i>et al.</i> ; Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells; J Virol.; Aug 2001; Vol. 75, No. 16; pp. 7769-7773.	
	Hasegawa <i>et al.</i> ; Mutations in the envelope protein of Japanese encephalitis virus affect entry into cultured cells and virulence in mice; Virology; 1992; Vol. 191; pp. 158-165.	
	Helenius; Alphavirus and flavivirus glycoproteins: structures and functions; Cell; June 2, 1995; Vol. 81; pp. 651-653.	
	Kimura <i>et al.</i> ; Analysis of virus-cell binding characteristics on the determination of Japanese encephalitis virus susceptibility; Arch Virol; 1994; Vol. 139; pp. 239-251.	
	Lee <i>et al.</i> ; Substitutions at the Putative Receptor-Binding Site of an Encephalitic Flavivirus Alter Virulence and Host Cell Tropism and Reveal for Glycosaminoglycans in Entry; J. of Virology; Oct. 2000; Vol. 74, No. 19; pp. 8867-8875.	
	Martínez-Barragán <i>et al.</i> ; Identification of a putative coreceptor on Vero cells that participates in dengue 4 virus infection; J Virol.; Sep 2001; Vol. 75, No. 17; pp. 7818-7827.	
	Ng <i>et al.</i> ; Possible involvement of receptors in the entry of Kunjin virus into Vero cells; Arch Virol.; 1988; Vol. 100; pp. 199-211.	
	Ng <i>et al.</i> ; Transport and budding at two distinct sites of visible nucleocapsids of West Nile (Sarafend) virus; J Med Virol.; 2001; Vol. 65; pp. 758-764.	

LA-FS1\314599v01\59419.010101

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/763,450
				Filing Date	January 22, 2004
				First Named Inventor	Mary NG Mah Lee
				Art Unit	1646
				Examiner Name	To be assigned
Sheet	4	of	4	Attorney Docket Number	59419-010101

## NON PATENT LITERATURE DOCUMENTS

	Putnak <i>et al.</i> ; A putative cellular receptor for dengue viruses; Nat Med.; Aug 1997; Vol. 3, No. 8; pp. 828-829.	
	Rappole <i>et al.</i> ; Migratory birds and spread of West Nile virus in the Western Hemisphere; Emerg Infect Dis; July-Aug 2000; Vol. 6, No. 4; pp. 319-328.	
	Sagara <i>et al.</i> ; 71-kilodalton heat shock cognate protein acts as a cellular receptor for syncytium formation induced by human Tcell lymphotropic virus type 1; J Virol; Jan 1998; Vol. 72, No. 1; pp. 535-541.	
	Salas-Benito <i>et al.</i> ; Identification of two surface proteins from C6/36 cells that bind dengue type 4 virus; J Virol; Oct 1997; Vol. 71, No. 10; pp. 7246-7252.	
	Schneider-Schaulies; Cellular receptors for viruses: links to tropism and pathogenesis; J Gen Virol.; 2000; Vol. 81, pp. 1413-1429.	
	Se-Thoe <i>et al.</i> ; Alteration of virus entry mode: a neutralization mechanism for Dengue-2 virus; J Med Virol; 2000; Vol. 62, pp. 364-376.	
	Taylor <i>et al.</i> ; The human cytomegalovirus receptor on fibroblasts is a 30-kilodalton membrane protein; J Virol; June 1990; Vol. 64, No. 6; pp. 2484-2490.	
	Thullier <i>et al.</i> ; Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism; J Gen Virol; 2001; Vol. 82, pp. 1885-1892.	
	Verdin <i>et al.</i> ; Characterization of a common high-affinity receptor for reovirus serotypes 1 and 3 on endothelial cells; J Virol; Mar 1989; Vol. 63, No. 3; pp. 1318-1 325.	

LA-FS1\314599v01\59419.010101

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.